Interrupting highly active antiretroviral therapy in patients with HIV

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 1, 2005, Pages 51-60

  Ananworanich, Jintanat ^a   Hirschel, Bernard ^b  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antiretroviral; Antiretroviral treatment; CD4 guided treatment; Highly active antiretroviral therapy; HIV 1; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Protease inhibitors; Scheduled treatment interruption; Structured treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; LYMPHOCYTE COUNT; MITOCHONDRIAL TOXICITY; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; VACCINATION; VIRUS LOAD; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS;

EID: 14044268795     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.1.51     Document Type: Review

References (69)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998).
2. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br. Med. J. 315(7117), 1194-1199 (1997).
3. Freedberg KA, Losina E, Weinstein MC et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344(11), 824-831 (2001).
4. Sendi PP, Bucher HC, Harr T et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS 13(9), 1115-1122 (1999).
5. Kaufmann GR, Smith D, Bucher HC et al. Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries. Expert Opin. Investig. Drugs 11(9), 1303-1313 (2002).
6. Hill A, Alcorn K. What is the minimum cost of HAART? Proceedings of the 2nd IAS Conference on HIV Pathogenesis and Treatment Paris, France, 13-16 July 2003 (Abstract 664).
7. Chakraborty R, Musoke R, Palakudy T, Cross AD, Agostino A. Management of severely immunocompromised human immunodeficiency virus Type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy. Clin. Infect. Dis. 36(11), 1483-1485 (2003).
8. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17(Suppl. 1), S141-S148 (2003).
9. Barbaro G, Di Lorenzo G, Cirelli A et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin. Ther. 25(9), 2405-2418 (2003).
10. Saves M, Chene G, Ducimetiere P et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin. Infect. Dis. 37(2), 292-298 (2003).
11. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med. 346(11), 811-820 (2002).
12. Norris PJ, Rosenberg ES. Cellular immune response to human immunodeficiency virus. AIDS 15(Suppl. 2), S16-S21 (2001).
13. Rosenberg ES, Altfeld M, Poon SH et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407(6803), 523-526 (2000).
14. Ortiz GM, Mixon DF, Trkola A et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104(6), R13-R18 (1999).
15. Fagard C, Oxenius A, Gunthard H et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch. Intern. Med. 163 (10), 1220-1226 (2003).
16. Montroni M, Monforte AD. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure. Scand. J. Infect. Dis. 35(Suppl. 106), 79-81 (2003).
17. Lisziewicz J, Lori F. Structured treatment interruptions in HIV/AIDS therapy. Microbes Infect. 4(2), 207-214 (2002).
18. Lisziewicz J, Rosenberg E, Lieberman J et al. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340(21), 1683-1684 (1999).
19. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. Predictors of plasma human immunodeficiency virus Type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J. Infect. Dis. 188(10), 1426-1432 (2003).
20. + T-cells in relation to HIV RNA load. J. Infect. Dis. 189(7), 1199-1208 (2004).
21. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus Type 1 infection. J. Virol. 68(9), 6103-6110 (1994).
22. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath WJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus Type 1 infection. N. Engl. J. Med. 37(18), 1267-1274 (1997).
23. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 290(5496), 1591-1593 (2000).
24. Dybul M, Chun TW, Yoder C et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc. Natl Acad. Sci. USA 98(26), 15161-15166 (2001).
25. Dybul M, Nies-Kraske E, Dewar R et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J. Infect. Dis. 189(11), 1974-1982 (2004).
26. Ananworanich J, Siangphoe U, Cardiello P et al. Comparing CD4-guided vs. 1 week on-1 week off vs. continuous HAART in 74 patients with chronic HIV infection: week 108 results. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 (Abstract WeOrB1283).
27. Ananworanich J, Nuesch R, Le Braz M et al. Failures of 1 week on-1 week: off antiretroviral therapies in a randomized trial. AIDS 17(15), F33-F37 (2003).
28. Dybul M. Symposium on structured treatment interruptions. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 (Abstract TuSy189).
29. Dybul M, Nies-Kraske E, Daucher M et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J. Infect. Dis. 188(3), 388-396 (2003).
30. Delfraissy J. Symposium on structured treatment interruptions. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 (Abstract TuSy188).
31. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A. Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T-cells: a controlled, prospective trial. AIDS 18(3), 439-446 (2004).
32. Fagard C, Bandelier C, Ananworanich J et al. Biphasic decline of CD4 cell count during scheduled treatment interruptions. AIDS (2004) (In press).
33. Yozviak JL, Doerfler RE, Woodward WC. Resuppression of virus load after interruption in treatment with nevirapine and two nucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis. 34(4), 547-550 (2002).
34. Ribaudo H, Clifford D, Gulick RM et al. Relationship between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response, and race: results from ACTG A5095/A5097s. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. San Fransisco, CA, USA, 8-11 February 2004 (Abstract 132).
35. Taylor S, Allen S, Fidler S et al. Stop study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. San Fransisco, CA, USA, 8-11 February 2004 (Abstract 131).
36. Jourdain G, Ngo-Giang-Huong N, Le Coeur S et al.. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351(3), 229-240 (2004).
37. Garcia F, Plana M, Arnedo M et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 17(1), 43-51 (2003).
38. Foli A, Maserati R, Barasolo G et al. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. Antivir. Ther. 9(1), 123-132 (2004).
39. Ruiz L, Martinez-Picado J, Romeu J et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 14(4), 397-403 (2000).
40. Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. J. Am. Med. Assoc. 286(23), 2981-2987 (2001).
41. Worthington MG, Ross JJ. Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. AIDS 17(14), 2145-2146 (2003).
42. Price RW, Paxinos EE, Grant RM et al. Cerebrospinal fluid response to structured treatment interruption after virologic failure. AIDS 15(10), 1251-1259 (2001).
43. Crespo M, Paradineiro JC, Ribera E et al. A case of multiorgan failure following interruption of antiretroviral treatment. Eur. J. Clin. Microbiol. Infect. Dis. 23(1), 63-65 (2004).
44. Ananworanich J, Phanuphak N, Nuesch R et al. Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 37(5), 723-725 (2003).
45. Fischer M, Joos B, Wong JK et al. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. J. Infect. Dis. 189(2), 273-285 (2004).
46. Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruption. Sex Transm. Infect. 79(1), 74(2003).
47. Nacsa J, Stanton J, Kunstman KJ et al. Emergence of cytotoxic T-lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIV mac251. Virology 305(1), 210-218 (2003).
48. Martini F, Poccia F, Goletti D et al. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vγ9Vδ2 T-cells in chronically infected patients undergoing structured treatment interruption. J. Infect. Dis. 186(6), 847-850 (2002).
49. + T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J. Acquir. Immune Defic. Syndr. 34(5), 475-481 (2003).
50. Fidler S, Oxenius A, Brady M et al. Virologic and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 16(15), 2049-2054 (2002).
51. Metzner KJ, Bonhoeffer S, Fischer M et al. Emergence of minor populations of human immunodeficiency virus Type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 188(10), 1433-1443 (2003).
52. Deeks SG, Grant RM, Wrin T et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17(3), 361-370 (2003).
53. Martinez-Picado J, Morales-Lopetegi K, Wrin T et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 16(6), 895-899 (2002).
54. Nuesch R, Ananworanich A, Sirivichayakul S et al. Development of resistance after CD4 guided structured treatment interruptions in HIV infected patients treated with highly active antiretroviral therapy after dual nucleoside treatment. Clin. Infect. Dis. (2004) (In Press).
55. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L. Drug resistance mutations during structured treatment interruptions. Antivir. Ther. 8(5), 411-415 (2003).
56. Wolf K, Young J, Rickenbach M et al. Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. J. Acquir. Immune Defic. Syndr. 33(4), 494-499 (2003).
57. Gulick RM. Structured treatment interruption in patients infected with HIV: a new approach to therapy. Drugs 62(2), 245-253 (2002).
58. D'Offizi G, Montesano C, Agrati C et al. Expansion of preterminally differentiated CD8 T-cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. AIDS 16(18), 2431-2438 (2002).
59. Oxenius A, Price DA, Gunthard HF et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl Acad. Sci. USA 99(21), 13747-13752 (2002).
60. Oxenius A, McLean AR, Fischer M et al. Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J. Virol. 76(20), 10169-10176 (2002).
61. 3. J. Acquir. Immune Defic. Syndr. 36(3), 791-799 (2004).
62. Oxenius A. Hirschel B. Structured treatment interruptions in HIV infection: benefit or disappointment? Expert Rev. Anti Infect. Ther. 1(1), 129-139 (2003).
63. Halfon P, Durant J, Clevenbergh P et al. Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions. AIDS 17(9), 1351-1361 (2003).
64. Gianotti N, Soria A, Galli L et al. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. J. Med. Virol. 72(2), 181-186 (2004).
65. Martinez-Picado J, Frost SD, Izquierdo N et al. Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J. Virol. 76(23), 12344-12348 (2002).
66. Lawrence J, Mayers DL, Hullsiek KH et al. Structured treatment interruption in patients with multi-drug resistant human immunodeficiency virus. N. Engl. J. Med. 349(9), 837-846 (2003).
67. Ruiz L, Ribera E, Bonjoch A et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J. Infect. Dis. 188(7), 977-985 (2003).
68. Katlama C, Dominguez S, Gourlain K et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 18(2), 217-226 (2004).
69. Hirschel B. Beware of drug holidays before HIV salvage therapy. N. Engl. J. Med. 349(9), 827-828 (2003).